Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT07085702
Registration number
NCT07085702
Ethics application status
Date submitted
11/07/2025
Date registered
25/07/2025
Date last updated
11/08/2025
Titles & IDs
Public title
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults
Query!
Scientific title
A Phase 1 Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Vaccine Against Group A Streptococcus Pyogenes (Strep A) With Alum or AS37 in Healthy Adults 18 to 25 Years of Age in Australia
Query!
Secondary ID [1]
0
0
75A50122C00028
Query!
Secondary ID [2]
0
0
217935
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Streptococcal Infections
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Low dose Strep A Alum
Treatment: Other - Medium dose Strep A Alum
Treatment: Other - High dose Strep A Alum
Treatment: Other - Low dose Strep A AS37
Treatment: Other - Medium dose Strep A AS37
Treatment: Other - High dose Strep A AS37
Treatment: Drugs - Strep A Alum Placebo
Experimental: Low dose Strep A Alum Group - Participants randomized to receive 3 doses of Low dose Strep A Alum vaccine on Day 1, Day 31, and Day 121.
Experimental: Medium dose Strep A Alum Group - Participants randomized to receive 3 doses of Medium dose Strep A Alum vaccine on Day 1, Day 31, and Day 121.
Experimental: High dose Strep A Alum Group - Participants randomized to receive 3 doses of High dose Strep A Alum vaccine on Day 1, Day 31, and Day 121.
Experimental: Low dose Strep A AS37 Group - Participants randomized to receive 3 doses of Low dose Strep A AS37 vaccine on Day 1, Day 31, and Day 121.
Experimental: Medium dose Strep A AS37 Group - Participants randomized to receive 3 doses of Medium dose Strep A AS37 vaccine on Day 1, Day 31, and Day 121.
Experimental: High dose Strep A AS37 Group - Participants randomized to receive 3 doses of High dose Strep A AS37 vaccine on Day 1, Day 31, and Day 121.
Placebo comparator: Strep A Alum Placebo Group - Participants randomized to receive 3 doses of Strep A Alum Placebo on Day 1, Day 31, and Day 121.
Treatment: Other: Low dose Strep A Alum
Low dose Strep A Alum vaccine will be administered intramuscularly (IM)
Treatment: Other: Medium dose Strep A Alum
Medium dose Strep A Alum vaccine will be administered IM
Treatment: Other: High dose Strep A Alum
High dose Strep A Alum vaccine will be administered IM
Treatment: Other: Low dose Strep A AS37
Low dose Strep A AS37 vaccine will be administered IM
Treatment: Other: Medium dose Strep A AS37
Medium dose Strep A AS37 vaccine will be administered IM
Treatment: Other: High dose Strep A AS37
High dose Strep A AS37 vaccine will be administered IM
Treatment: Drugs: Strep A Alum Placebo
Strep A Alum Placebo will be administered IM
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants with solicited administration site events
Query!
Assessment method [1]
0
0
Solicited administration-site events include pain, redness, and swelling at the administration site.
Query!
Timepoint [1]
0
0
Up to 7 days after each study intervention administration occurring at Day 1, Day 31, and Day 121
Query!
Primary outcome [2]
0
0
Number of participants with solicited systemic events
Query!
Assessment method [2]
0
0
Solicited systemic events include fever, headache, myalgia (muscle pain), arthralgia (joint pain), and fatigue (tiredness). Fever is defined as body temperature equal to or above 38.0°C. The preferred location for measuring temperature is the axilla.
Query!
Timepoint [2]
0
0
Up to 7 days after each study intervention administration occurring at Day 1, Day 31, and Day 121
Query!
Primary outcome [3]
0
0
Number of participants with unsolicited adverse events (AEs)
Query!
Assessment method [3]
0
0
An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and nonserious AEs.
Query!
Timepoint [3]
0
0
Up to 30 days after each study intervention administration occurring at Day 1, Day 31, and Day 121
Query!
Primary outcome [4]
0
0
Number of participants with laboratory abnormalities
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
7 days after each study intervention administration at Day 8, Day 38, and Day 128
Query!
Primary outcome [5]
0
0
Number of participants with adverse events of special interest (AESIs)
Query!
Assessment method [5]
0
0
AESIs include potential immune-mediated disorders (pIMDs) and rheumatic carditis.
Query!
Timepoint [5]
0
0
From Day 1 to Day 301
Query!
Primary outcome [6]
0
0
Number of participants with serious adverse events (SAEs)
Query!
Assessment method [6]
0
0
An SAE is defined as any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongs existing hospitalization, results in disability/incapacity, abnormal pregnancy outcomes, or other medically significant events.
Query!
Timepoint [6]
0
0
From Day 1 to Day 301
Query!
Primary outcome [7]
0
0
Number of participants with AEs leading to withdrawal from the study or to discontinuation of study vaccine
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
From Day 1 to Day 301
Query!
Secondary outcome [1]
0
0
Geometric mean concentrations of immunoglobulin G (IgG) against Streptolysin O (SLO), S. pyogenes Cell Envelope Protease (SpyCEP), S. pyogenes Adhesion and Division protein (SpyAD), and Group A Carbohydrate (GAC), as measured by multiplex immunoassay
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Before each study intervention (Day 1, Day 31, and Day 121), 30 days after each study intervention (Day 31, Day 61, and Day 151), and 7 days and 6 months after the third study intervention administration (Days 128 and 301, respectively)
Query!
Secondary outcome [2]
0
0
Geometric mean fold increase of IgG against SLO, SpyCEP, SpyAD, and GAC, as measured by multiplex immunoassay
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
30 days after each study intervention administration compared to before each study intervention administration (Day 31 versus Day 1, Day 61 versus Day 31, and Day 151 versus Day 121) and to before study intervention administration (Day 1)
Query!
Secondary outcome [3]
0
0
Number of participants with greater than or equal to (>=) 2-fold and >=4 fold increase in IgG antibody concentration against SLO, SpyCEP, SpyAD, and GAC, as measured by multiplex immunoassay
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
30 days after each study intervention administration (Day 31, Day 61, and Day 151) compared to before study intervention administration (Day 1)
Query!
Eligibility
Key inclusion criteria
* Participants, who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., completion of electronic diaries [eDiaries], return for follow-up visits).
* Written or witnessed/thumb-printed informed consent obtained from the participant prior to performance of any study-specific procedure.
* Healthy participants as established by medical history, clinical examination, and laboratory assessments.
* Satisfies all screening requirements.
* Male and female participants between and including 18 and 25 years of age at the time of informed consent.
* Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as premenarche, postmenopause, or had current bilateral tubal ligation or occlusion, hysterectomy, or bilateral ovariectomy.
* Female participants who are of childbearing potential may be enrolled in the study if the participant:
* has practiced adequate contraception for 1 month prior to study intervention administration, and
* has a negative pregnancy test on the day of study intervention administration, and
* has agreed to continue adequate contraception during the entire study intervention administration period and for 1 month after completion of the study intervention administration series.
* Male participants who are sexually active with a female partner of childbearing potential are eligible to participate if they agree to have their partner use a highly effective method of contraception for 1 month prior to the first study intervention administration until 1 month after completion of the study intervention administration series.
* Male participants must refrain from donating sperm for 1 month prior to the first study intervention administration until 1 month after completion of the study intervention administration series.
* Participants seronegative for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C at Screening.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
25
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* History of rheumatic fever or rheumatic heart disease during the lifetime of the participant as confirmed during interview with the participant or as documented in medical records.
* Recent history of pharyngitis in the last four (4) weeks will be excluded. These participants can be rescreened once the recent pharyngitis passes the 4-weeks period. Participants with symptoms of acute pharyngitis at Screening will be tested with a Strep A rapid antigen test. Those with positive results will be excluded.
* Progressive, unstable, or uncontrolled clinical conditions.
* History (known or suspected) of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
* Hypersensitivity (e.g., allergy) to medicinal products or medical equipment anticipated to be used in this study.
* Clinical conditions that represents a contraindication for IM vaccination or blood draws.
* Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.
* Acute disease and/or fever (defined as temperature >=38.0°C) at the time of enrollment.
* Any Grade >=2 and/or clinically significant hematological and/or biochemical laboratory abnormality.
* Any echocardiographic/Doppler Echo findings consistent with carditis at Screening.
* Recurrent history or uncontrolled neurological disorders or seizures.
* Medical history or family history of autoimmune disease and other pIMDs.
* Family history of acute rheumatic fever.
* Acute or chronic illness, or clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality.
* Any other clinical condition that might pose additional risk to the participant due to participation in the study.
* Administration of long-acting immune-modifying drugs (e.g., infliximab) at any time prior to the administration of the first dose of study intervention(s) or planned administration during the study period.
* Prior receipt of an experimental Strep A vaccine.
* Use of any investigational or nonregistered product (drug, vaccine, or medical device) other than the study interventions during the period starting 30 days before the first dose of study intervention (Day -30 to Day 1), or their planned use during the study period.
* Receipt of a vaccine not foreseen by the study protocol administered during the period starting at 21 days before the first dose of study intervention (28 days before the first dose, in case of live vaccines) and ending after the last dose of study intervention administration.
* Administration of immunoglobulins and/or any blood products or plasma derivatives, or bone marrow transplantation, during the period starting 3 months before administration of the first dose of study intervention(s) or planned administration during the study period.
* Chronic administration (defined as >14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first dose of study intervention. For corticosteroids, this means prednisone equivalent >=20 mg/day for adult participants. Inhaled, topical, intra-articular, and intranasal steroids are allowed.
* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug, vaccine, or invasive medical device).
* Pregnant or lactating female participant.
* Participant who is planning to become pregnant or planning to discontinue contraceptive precautions.
* History of or current chronic alcohol consumption and/or drug abuse.
* Any study personnel or their immediate dependents, family, or household members.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/07/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/11/2026
Query!
Actual
Query!
Sample size
Target
108
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Botany
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Camberwell
Query!
Recruitment postcode(s) [1]
0
0
2019 - Botany
Query!
Recruitment postcode(s) [2]
0
0
3124 - Camberwell
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
HHS/BARDA
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Wellcome Trust
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
DHSC/GAMRIF
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
Germany/BMBF
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant. The Strep A vaccine will be tested for the first time in humans, in healthy young adults 18 to 25 years of age. The study will also assess if the vaccines have any immediate reactions and if they induce an immune response. A low, medium, and high dose of each formulation of the vaccine will be assessed in sequence.
Query!
Trial website
https://clinicaltrials.gov/study/NCT07085702
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
King C Cheung
Query!
Address
0
0
Emeritus Research
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
US GSK Clinical Trials Call Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
877-379-3718
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About\_GSK\_Patient\_Level\_Data\_Sharing\_Final\_13July2023.pdf
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Query!
Available to whom?
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT07085702
Download to PDF